stanozolol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| androgens/anabolic steroids | 2477 | 10418-03-8 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A synthetic steroid that has anabolic and androgenic properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1194)
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 5 | mg | O |
| 3.50 | mg | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| S (Water solubility) | 1 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Bocci G, Oprea TI, Benet LZ |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 9, 1962 | FDA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drug abuse | 128.06 | 89.61 | 45 | 324 | 99051 | 34857511 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drug abuse | 135.03 | 93.89 | 44 | 353 | 162647 | 79581344 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A14AA02 | ALIMENTARY TRACT AND METABOLISM ANABOLIC AGENTS FOR SYSTEMIC USE ANABOLIC STEROIDS Androstan derivatives |
| MeSH PA | D045930 | Anabolic Agents |
| MeSH PA | D000728 | Androgens |
| MeSH PA | D006728 | Hormones |
| CHEBI has role | CHEBI:50113 | androgene |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Hereditary angioneurotic edema | indication | 82966003 | DOID:14735 |
| Antithrombin III deficiency | off-label use | 36351005 | DOID:3755 |
| Aplastic anemia | off-label use | 306058006 | DOID:12449 |
| Fibrinogen Excess | off-label use | ||
| Hypercholesterolemia | contraindication | 13644009 | |
| Humoral hypercalcemia of malignancy | contraindication | 47709007 | |
| Nephrotic syndrome | contraindication | 52254009 | DOID:1184 |
| Heart disease | contraindication | 56265001 | DOID:114 |
| Hypercalcemia | contraindication | 66931009 | DOID:12678 |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Neoplasm of prostate | contraindication | 126906006 | DOID:10283 |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Benign prostatic hyperplasia | contraindication | 266569009 | |
| Pregnancy, function | contraindication | 289908002 | |
| Breastfeeding (mother) | contraindication | 413712001 | |
| Disorder of coronary artery | contraindication | 414024009 | |
| Breast Carcinoma in Males | contraindication |
🐶 Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Cats | Anabolic steroid treatment | Indication |
| Dogs | Anabolic steroid treatment | Indication |
🐶 Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| Winstrol-V Tablets | Zoetis Inc. | 1 |
| Winstrol-V Sterile Suspension | Zoetis Inc. | 1 |
| Winstrol-V Chewable Tablets | Zoetis Inc. | 1 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 4.67 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Androgen receptor | Nuclear hormone receptor | AGONIST | CHEMBL | CHEMBL | |||||
| Adenosine receptor A3 | GPCR | Ki | 5.33 | DRUG MATRIX | |||||
| Estrogen receptor | Nuclear hormone receptor | Ki | 7.50 | DRUG MATRIX | |||||
| Cytochrome P450 2C9 | Enzyme | IC50 | 5.95 | DRUG MATRIX | |||||
| Cytochrome P450 2C19 | Enzyme | IC50 | 7.32 | DRUG MATRIX | |||||
| Cytochrome P450 2D6 | Enzyme | IC50 | 5.03 | DRUG MATRIX | |||||
| Androgen receptor | Transcription factor | Ki | 7.82 | DRUG MATRIX | |||||
| Progesterone receptor | Transcription factor | Ki | 6.32 | DRUG MATRIX |
External reference:
| ID | Source |
|---|---|
| 4018261 | VUID |
| N0000146591 | NUI |
| D00444 | KEGG_DRUG |
| 4018261 | VANDF |
| C0038149 | UMLSCUI |
| CHEBI:9249 | CHEBI |
| CHEMBL2079587 | ChEMBL_ID |
| DB06718 | DRUGBANK_ID |
| D013197 | MESH_DESCRIPTOR_UI |
| 25249 | PUBCHEM_CID |
| 10369 | IUPHAR_LIGAND_ID |
| 958 | INN_ID |
| 4R1VB9P8V3 | UNII |
| 10032 | RXNORM |
| 5510 | MMSL |
| d00565 | MMSL |
| 001252 | NDDF |
| 126103004 | SNOMEDCT_US |
| 66602007 | SNOMEDCT_US |
Pharmaceutical products:
None